Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Open in API
Filings indexed 1,720 across all filing types
Latest filing 2023-01-30 Director's Dealing
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2023-01-30 English
FILING REGENERON PHARMACEUTICALS, INC.
Major Shareholding Notification
2023-01-11 English
PRIMARY DOCUMENT
Director's Dealing
2023-01-10 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a corporate update presented at the 41st Annual J.P. Morgan Healthcare Conference, with preliminary unaudited financial results and other operational information. It references a presentation (Exhibit 99.1) but does not contain full financial statements or detailed quarterly or annual financial reports. The document is not an earnings release (ER) because it provides more detailed commentary and a presentation rather than just key highlights. It is not an Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements. It is not a Management Discussion & Analysis (MDA) because it is a current report filing with a corporate update and preliminary results. The document is best classified as a Regulatory Filing (RNS) because it is a current report (Form 8-K) disclosing material events and preliminary financial information without full financial statements or detailed analysis. The length (9913 characters) and content confirm it is a substantive filing but not a full financial report or presentation itself, rather an official regulatory announcement of such information.
2023-01-09 English
PRIMARY DOCUMENT
Director's Dealing
2023-01-05 English
PRIMARY DOCUMENT
Director's Dealing
2023-01-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.